The Zephyr AI Platform: Transforming Complex Data into Actionable Insights

Built to operate on the complex, fragmented data generated in clinical settings every day, the Zephyr AI platform unifies advanced machine learning with one of the world’s largest real-world clinicogenomic datasets. Our interoperable tools work together to uncover predictive signals, refine patient stratification, and accelerate insight generation across the drug development lifecycle. From real-world cohort construction to AI-enabled companion diagnostics, Zephyr empowers biopharma and diagnostics partners to make smarter decisions—faster, and at scale.

AIM-Bx: AI-Enabled Multi-Modal Biomarkers for Precision Oncology

AIM-Bx is Zephyr AI’s proprietary software product that uses advanced machine learning to stratify patients based on molecular, clinical, and drug-specific data. Trained on hundreds of thousands of drug–tumor contexts, it delivers actionable, biologically interpretable predictions validated in real-world settings—and works seamlessly with existing NGS panels, requiring no bespoke assays.

Key Differentiators of Zephyr’s AIM-Bx

Zephyr Nexus: Real-World Intelligence at Scale

Zephyr Nexus is a real-world data platform that transforms complex, multimodal patient data into analysis-ready insights. Paired with Zephyr’s extensive in-house real-world clinicogenomic resources, Nexus streamlines data integration, cohort construction, and outcomes analysis—unlocking both internal model development and partner-facing applications across the development lifecycle.

Nexus powers Zephyr’s work in risk modeling, value-based care, and predictive analytics for high-cost therapies. It also enables high-throughput clinical queries across one of the world’s largest clinicogenomic datasets, delivering clinical intelligence for translational research, biomarker discovery, HEOR, trial optimization, and regulatory decision-making.

Key Differentiators of Zephyr Nexus

Precision Oncology Data: Enabling Discovery, Validation & Prospective Research

Zephyr’s subsidiary Aster Insights™ provides access to Total Cancer Care®—the world’s largest and longest-running observational oncology study, conducted in partnership with the ORIEN® network. With over 400,000 patients consented for lifetime follow-up, this unique resource enables deep discovery research, real-world cohort analysis, and bespoke data generation across the development lifecycle.

Key Capabilities

Together with Zephyr’s machine learning platforms, this offering empowers precision medicine innovation from discovery through development, supporting pharma, diagnostics, and academic partners at every stage.